THERAPEUTISCHE UMSCHAU最新文献

[Phosphatidyethanol in the diagnosis and treatment of alcohol-related disorders]. [磷脂乙醇在酒精相关疾病诊断和治疗中的应用]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2025-04-01 DOI: 10.23785/TU.2025.02.003

Philippe Pfeifer, Panagiota Ntinopoulou, Matthias Bantle, Wolfgang Weinmann

{"title":"[Phosphatidyethanol in the diagnosis and treatment of alcohol-related disorders].","authors":"Philippe Pfeifer, Panagiota Ntinopoulou, Matthias Bantle, Wolfgang Weinmann","doi":"10.23785/TU.2025.02.003","DOIUrl":"https://doi.org/10.23785/TU.2025.02.003","url":null,"abstract":"Introduction: The diagnosis and treatment of alcohol use disorders often pose complex questions and challenges for healthcare professionals. In addition to the established indirect biomarkers (e. g. carbohydrate-deficient transferrin [CDT]), clinical research in recent years has produced increasingly valuable findings on the use of direct biomarkers. In this regard, the marker phosphatidyltethanol (PEth), a lipid metabolite that is formed during the breakdown of ethanol, is stored in the erythrocytes, should be emphasized in particular. The advantage of targeted use of PEth in general medical and psychiatric practice to improve diagnostics and therapy has been demonstrated in clinical studies in recent years. Together with the established screening instruments (e. g. AUDIT), PEth can lead to greater validity in the diagnosis of alcohol use disorders. Targeted use of PEth can be used to control treatment goals (e. g. abstinence vs. controlled drinking) and monitor them longitudinally. The determination of PEth generally facilitates and improves communication with patients and can contribute to a destigmatization of the clinical picture, as certain feelings of shame and inhibitions in doctor-patient contact could be diminished.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 2","pages":"48-52"},"PeriodicalIF":0.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143990952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Interventional psychiatric procedures and novel substances for the treatment of affective disorders: An overview and outlook]. [介入精神病学程序和治疗情感性障碍的新物质：综述和展望]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2025-04-01 DOI: 10.23785/TU.2025.02.005

Tobias Bracht, Daniela Hubl, Kristina Adorjan, Gianluca Florineth, Leila M Soravia, Bogdan Draganski, Sebastian Olbrich, Annette Brühl, Niklaus Denier

{"title":"[Interventional psychiatric procedures and novel substances for the treatment of affective disorders: An overview and outlook].","authors":"Tobias Bracht, Daniela Hubl, Kristina Adorjan, Gianluca Florineth, Leila M Soravia, Bogdan Draganski, Sebastian Olbrich, Annette Brühl, Niklaus Denier","doi":"10.23785/TU.2025.02.005","DOIUrl":"https://doi.org/10.23785/TU.2025.02.005","url":null,"abstract":"Introduction: Depression is one of the most common mental disorders. The effectiveness of pharmacological and psychotherapeutic treatments is well documented. Remission rates are around 67 % for pharmacological antidepressant initial and secondary treatment of a depressive episode in unipolar disorders. However, patients with a depressive episode who do not respond to at least two successive attempts at pharmacological antidepressant treatment have significantly lower remission rates. Particularly in this subgroup with difficult-to-treat depression, brain stimulation procedures and treatment with novel substances represent innovative and effective treatment options that complement pharmacotherapy and psychotherapy. The aim of this paper is to provide an overview and outlook on the following treatment procedures: repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), ketamine/esketamine, transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), and psychedelic-assisted psychotherapy (PAT). An outlook on selected current developments with the aim of a procedure-specific, individualized indication will be given.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 2","pages":"57-61"},"PeriodicalIF":0.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[ASSIP flex sustainable suicide prevention: a treatment programme for people who have attempted suicide]. [assp灵活的可持续自杀预防：针对有自杀企图的人的治疗方案]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2025-04-01 DOI: 10.23785/TU.2025.02.006

Adriana Frei, Lara Marie Aschenbrenner, Marie-Anna Sedlinskà, Franziska von Strauss Und Torney, Katja Cattapan, Laurent Michaud, Stéphane Saillant, Sebastian Olbrich, Stephanie Homan, Sophia Werdin, Kaspar Wyss, Kristina Adorjan, Sebastian Walther, Anja Gysin-Maillart

{"title":"[ASSIP flex sustainable suicide prevention: a treatment programme for people who have attempted suicide].","authors":"Adriana Frei, Lara Marie Aschenbrenner, Marie-Anna Sedlinskà, Franziska von Strauss Und Torney, Katja Cattapan, Laurent Michaud, Stéphane Saillant, Sebastian Olbrich, Stephanie Homan, Sophia Werdin, Kaspar Wyss, Kristina Adorjan, Sebastian Walther, Anja Gysin-Maillart","doi":"10.23785/TU.2025.02.006","DOIUrl":"10.23785/TU.2025.02.006","url":null,"abstract":"Introduction: Background: ASSIP flex is a structured, low-threshold brief therapy for individuals with suicidal behavior. As a flexible treatment approach, it can be delivered in inpatient, outpatient, and home settings. This study examines its feasibility, acceptability, and clinical application in routine practice. Method: In an observational pre-post study, 105 patients (53.8 % women; M = 38.8 years, SD = 15.2) were interviewed before (t0) and after (t1) the ASSIP flex brief intervention. Sociodemographic characteristics, feasibility aspects, and clinical variables were assessed. In addition, nine therapists evaluated implementation and acceptability. Results: ASSIP flex was mainly recommended by professionals (57.3 %) and showed high acceptability, with its adaptability across different treatment settings cited as a key advantage. Patients demonstrated a significant reduction in suicidal ideation (t104 = 4.5, p 0.001) and depressive symptoms (t104 = 6.0, p 0.001), as well as an increase in self-efficacy (t104 = -2.3, p 0.05). Higher perceived effectiveness of ASSIP flex correlated with lower suicidal ideation (r = -0.28, p 0.01) and depressive symptoms (r = -0.29, p 0.01), as well as increased self-efficacy (r = 0.22, p 0.05). Conclusion: ASSIP flex is a versatile treatment option for individuals with suicidal behavior. The results confirm its potential as a promising addition to existing care structures and its ability to address a critical gap in post-attempt care.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 2","pages":"62-68"},"PeriodicalIF":0.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Personalised treatment planning for patients with depression - a guide that takes into account biological, psychological and social aspects]. [抑郁症患者的个性化治疗计划——一个考虑生物、心理和社会方面的指南]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2025-04-01 DOI: 10.23785/TU.2025.02.002

Katja Cattapan, Paul Lukas, Debora Verciglio, Tobias Ballweg, Kristina Adorjan

{"title":"[Personalised treatment planning for patients with depression - a guide that takes into account biological, psychological and social aspects].","authors":"Katja Cattapan, Paul Lukas, Debora Verciglio, Tobias Ballweg, Kristina Adorjan","doi":"10.23785/TU.2025.02.002","DOIUrl":"https://doi.org/10.23785/TU.2025.02.002","url":null,"abstract":"Introduction: The diagnosis of \"depression\" encompasses very heterogeneous clinical pictures. There are different treatment methods for depression, with psychopharmacological and psychotherapeutic treatment strategies being particularly relevant. There is increasing evidence that a personalised therapeutic approach, which takes into account individual biological, psychological and social vulnerability factors and resources, is useful. The article describes the specific impact factors that are important for treatment planning. In the presence of stressful childhood experiences, which are particularly relevant for the development of chronic depression, these should be specifically considered in therapy. As the inadequate satisfaction of basic psychological needs is a central factor in the development and maintenance of depression, the individual case concept helps to analyse psychological conflicts and motivational goals in greater depth. Two checklists are presented as instruments for this purpose, which - taking into account the biological and psychosocial dimensions, both in regard of deficits and resources - identify the factors relevant for treatment planning.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 2","pages":"42-47"},"PeriodicalIF":0.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Current psychopharmacological therapy for depression]. [当前抑郁症的心理药理学治疗]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2025-04-01 DOI: 10.23785/TU.2025.02.001

Kristina Adorjan

引用次数: 0

[Adjustment disorders according to ICD-11 in the context of somatic illnesses]. [根据ICD-11在躯体疾病背景下的适应障碍]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2025-04-01 DOI: 10.23785/TU.2025.02.004

Astrid Habenstein, Kristina Barbara Rohde, Kristina Adorjan

引用次数: 0

[Glucocorticoid-induced Osteoporosis; Epidemiology, Pathogenesis and Treatment]. [激素性骨质疏松症;流行病学、发病机制和治疗[j]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2025-02-01 DOI: 10.23785/TU.2025.01.005

Anna Madrid, Catherine Lamm, Daniel Aeberli

{"title":"[Glucocorticoid-induced Osteoporosis; Epidemiology, Pathogenesis and Treatment].","authors":"Anna Madrid, Catherine Lamm, Daniel Aeberli","doi":"10.23785/TU.2025.01.005","DOIUrl":"10.23785/TU.2025.01.005","url":null,"abstract":"Introduction: Glucocorticoid (GC) therapy has been shown to be associated with a dose-dependent significantly elevated risk of osteoporosis and fractures. It is estimated that about 3 % of the population are prescribed systemic GC on a daily basis, and approximately 30-50 % of patients treated with GC experience an osteoporotic fracture. Evidence has been mounting that inhaled, topical, and locally infiltrated GC also adversely affect bone mineral density. At the cellular level, GC have been shown to activate osteoclasts and inhibit the activity of osteoblasts and osteocytes, resulting in a loss of bone mass and a deterioration in bone quality, thereby increasing fracture risk. Patients prescribed a daily dosage of ≥ 5 mg of prednisone equivalents for a period of at least three months should undergo a bone density assessment and a fracture risk evaluation. Lifestyle modifications, including physical activity as well as calcium and vitamin D supplementation are recommended for all patients with GC therapy. In cases of a very high risk for fracture, the administration of osteoanabolic therapy followed by antiresorptive therapy is imperative. In patients with high fracture risk, antiresorptive therapy is recommended, whereas for those at moderate/low risk for fracture selective estrogen receptor modulators or oral bisphosphonates can be considered.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 1","pages":"20-25"},"PeriodicalIF":0.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Osteoporosis therapy - Update 2025, Part 2: Sequential osteoporosis therapy]. [骨质疏松治疗-更新2025，第2部分：顺序骨质疏松治疗]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2025-02-01 DOI: 10.23785/TU.2025.01.007

Christian Meier, Judith Everts-Graber, Serge Ferrari

引用次数: 0

[Risk of jaw osteonecrosis and atypical femoral fracture: how to inform patients with osteoporosis?] 颌骨坏死和非典型股骨骨折的风险：骨质疏松症患者如何告知？］

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2025-02-01 DOI: 10.23785/TU.2025.01.008

Albrecht W Popp

引用次数: 0

[The importance of bone remodelling parameters in the management of osteoporosis]. [骨重塑参数在骨质疏松症治疗中的重要性]。

IF 0.2

THERAPEUTISCHE UMSCHAU Pub Date : 2025-02-01 DOI: 10.23785/TU.2025.01.002

Devran Topyürek, Christian Meier, Marius E Kränzlin

{"title":"[The importance of bone remodelling parameters in the management of osteoporosis].","authors":"Devran Topyürek, Christian Meier, Marius E Kränzlin","doi":"10.23785/TU.2025.01.002","DOIUrl":"10.23785/TU.2025.01.002","url":null,"abstract":"Introduction: Bone is continuously remodelled. Bone turnover markers reflect the activity of osteoblasts and osteoclasts during remodelling. Collagen synthesis by osteoblasts is reflected by the formation of bone-specific alkaline phosphatase (BALP), osteocalcin (OC) and procollagen N-propeptides (P1NP). During bone resorption, fragments of collagen (N- and C-terminal telopeptides, pyridinolines) and tartrate-resistant acid phosphatase (TRACP) are released. These markers enable a dynamic assessment of bone remodelling. P1NP is recommended as a reference marker for bone formation and ßCTX for bone resorption. Using and, above all, interpreting the results of bone turnover markers, it is impor-tant to take into account the various sources of variability of these markers, such as diurnal rhythm, day-to-day fluctuations, food intake and also the stability of the marker after blood sampling. The most important area for the clinical use of bone turnover markers is the monitoring of antiresorptive or anabolic treatments of osteoporosis. A short-term decrease in bone turnover during antiresorptive therapy correlates with an increase in bone density after 1-2 years and a decrease in fracture risk. The bone formation markers, especially P1NP, correlate with the increase in bone mineral density on anabolic treatment.","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 1","pages":"2-9"},"PeriodicalIF":0.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0